9/22/2009 - The preliminary results of the trial suggest that patients who received treatment showed a trend towards stabilization of the disease
The line of investigation was based on the systematic practice of therapeutic plasmapheresis with Human Albumin
Grifols in patients with this disease
Back in 2005, the Clinical Research Department at Grifols designed a clinical study to explore whether the use of successive plasmapheresis with human albumin in patients with Alzheimer’s disease could mobilize the beta amyloid protein implicated in the disease from the cerebrospinal fluid into the blood. Dr. Boada, Medical Director of the Fundació ACE and Clinician Head at the Neurology Service at the Vall d’Hebron Hospital, Barcelona, agreed to conduct this preliminary study, and the positive results with respect to the cognitive status of the patients treated gave rise to the design and development of a clinical trial with the participation of three hospitals in Spain and two in the United States.
The interim results of this trial, recently published in the journal
Drug News and Perspectives (DOI: 10.1358/dnp.2009.22.6.1395256) highlight both the improvement of cognitive status of patients treated and the evidence that amyloid beta is mobilized in the blood of patients who undergo therapeutic plasmapheresis with albumin. However, it is necessary to complete the clinical trial before the improved cognitive development can be confirmed...
Grifols' Press Release -
November 10, 2009 — SRI International, an independent nonprofit research and development organization, announced that its Center for Neuroscience has entered into a research collaboration with F. Hoffmann-La Roche to study procedures and treatments for cognition impairments in neurological and psychiatric conditions such as Alzheimer's disease, depression and schizophrenia.
Research will take place in SRI's laboratories in Menlo Park, California... SRI International's press release -
